SUCLG2 and Right ventricular cardiomyopathy: The pathways involved in the antagonistic GSK-126 group were the bacterial invasion of epithelial cell pathway and the arrhythmogenic right ventricular cardiomyopathy (ARVC) pathway, involving proteins of the PSMD family such as CTNNB1, CTNNA1, PHB1, and SUCLG2 (Figure 6F).